These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 26463630)

  • 21. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.
    Höpfner M; Huether A; Sutter AP; Baradari V; Schuppan D; Scherübl H
    Biochem Pharmacol; 2006 May; 71(10):1435-48. PubMed ID: 16530734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
    Cani A; Simioni C; Martelli AM; Zauli G; Tabellini G; Ultimo S; McCubrey JA; Capitani S; Neri LM
    Oncotarget; 2015 Mar; 6(9):6597-610. PubMed ID: 25788264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
    Torki S; Soltani A; Shirzad H; Esmaeil N; Ghatrehsamani M
    Biomed Pharmacother; 2017 Aug; 92():39-45. PubMed ID: 28528184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.
    Bertrand FE; Steelman LS; Chappell WH; Abrams SL; Shelton JG; White ER; Ludwig DL; McCubrey JA
    Leukemia; 2006 Jul; 20(7):1254-60. PubMed ID: 16642049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells.
    Shrivastava S; Kulkarni P; Thummuri D; Jeengar MK; Naidu VG; Alvala M; Redddy GB; Ramakrishna S
    Apoptosis; 2014 Jul; 19(7):1148-64. PubMed ID: 24729100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.
    Mukohara T; Shimada H; Ogasawara N; Wanikawa R; Shimomura M; Nakatsura T; Ishii G; Park JO; Jänne PA; Saijo N; Minami H
    Cancer Lett; 2009 Sep; 282(1):14-24. PubMed ID: 19345478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PDK1 is a potential therapeutic target against angiosarcoma cells.
    Wada M; Horinaka M; Yasuda S; Masuzawa M; Sakai T; Katoh N
    J Dermatol Sci; 2015 Apr; 78(1):44-50. PubMed ID: 25726712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
    Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.
    Teo T; Yu M; Yang Y; Gillam T; Lam F; Sykes MJ; Wang S
    Cancer Lett; 2015 Feb; 357(2):612-23. PubMed ID: 25527453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Curcumol induces cell cycle arrest and apoptosis by inhibiting IGF-1R/PI3K/Akt signaling pathway in human nasopharyngeal carcinoma CNE-2 cells.
    Li X; Liu H; Wang J; Qin J; Bai Z; Chi B; Yan W; Chen X
    Phytother Res; 2018 Nov; 32(11):2214-2225. PubMed ID: 30069933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.
    Haagensen EJ; Kyle S; Beale GS; Maxwell RJ; Newell DR
    Br J Cancer; 2012 Apr; 106(8):1386-94. PubMed ID: 22415236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
    Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC.
    Heavey S; Cuffe S; Finn S; Young V; Ryan R; Nicholson S; Leonard N; McVeigh N; Barr M; O'Byrne K; Gately K
    Oncotarget; 2016 Nov; 7(48):79526-79543. PubMed ID: 27765909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
    Anderson JL; Park A; Akiyama R; Tap WD; Denny CT; Federman N
    PLoS One; 2015; 10(9):e0133610. PubMed ID: 26402468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.
    Watanabe T; Sato A; Kobayashi-Watanabe N; Sueoka-Aragane N; Kimura S; Sueoka E
    Anticancer Res; 2016 Jan; 36(1):95-102. PubMed ID: 26722032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of triple negative breast cancer cells with combination of mTOR1/2 inhibitor AZD8055 and MEK1/2 inhibitor PD0325901].
    Nan XY; Wu Y; Zhang LH; Yang ZJ
    Yao Xue Xue Bao; 2016 Oct; 51(10):1551-7. PubMed ID: 29932599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001.
    Baumann P; Hagemeier H; Mandl-Weber S; Franke D; Schmidmaier R
    Anticancer Drugs; 2009 Apr; 20(4):259-66. PubMed ID: 19240643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinase inhibitors of the IGF-1R as a potential therapeutic agent for rheumatoid arthritis.
    Tsushima H; Morimoto S; Fujishiro M; Yoshida Y; Hayakawa K; Hirai T; Miyashita T; Ikeda K; Yamaji K; Takamori K; Takasaki Y; Sekigawa I; Tamura N
    Autoimmunity; 2017 Aug; 50(5):329-335. PubMed ID: 28682648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.